Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →The deal, which involves a $700 million upfront payment, gives AbbVie access to ISB 2001, a clinical-stage first-in-class trispecific antibody currently being…
Glenmark Pharmaceuticals Ltd. today announced that its wholly-owned subsidiary Ichnos Glenmark Innovation (IGI) has entered into an exclusive global licensing…
In July 2025, AbbVie and Ichnos Glenmark Innovation linked up to take the bispecific attack on multiple myeloma one step further, adding another cancer marker…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
AbbVie obtained exclusive rights in North America, Europe, Japan, and Greater China to ISB 2001, a first-in-class CD38 x BCMA x CD3 trispecific antibody for R/R multiple myeloma, from Glenmark subsidiary IGI. Upfront $700M and up to $1.225B in milestones plus tiered royalties. Total ~$1.925B.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Ichnos Glenmark Innovation (IGI) (this deal) | 2025 | $1.9B | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2025 deals · AbbVie Inc. deals · Hematology deals